A federal judge in Delaware has ruled in favor of Exelixis in its Cabometyx patent fight with MSN Laboratories, effectively ...
Last week, the biotech sector was in focus, with regular pipeline and regulatory updates. Vanda Pharmaceuticals Inc. VNDA was ...
Exelixis (EXEL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Stephen Willey ...
In addition to the legal success, Exelixis has received an upgrade from B of A Securities. The firm has maintained a Buy rating and raised the price target from $30 to $32. This optimistic outlook ...
Cabometyx is already approved as a second-line treatment for HCC in people who have previously received Nexavar, along with first- and second-line approvals for RCC, with sales reaching $720 ...
Leerink Partners analyst Andrew Berens has maintained their neutral stance on EXEL stock, giving a Hold rating today. Andrew Berens has given ...
Exelixis (NASDAQ:EXEL) has released additional phase 3 data on Cabometyx (cabozantinib) in individuals with pancreatic neuroendocrine tumors (pNET) and with advanced extra-pancreatic ...
The European Commission has approved Ipsen’s Cabometyx for liver cancer, in adults previously treated with Bayer’s Nexavar. The commission granted a marketing authorisation for Cabometyx ...
Cabometyx (cabozantinib) is a brand-name oral tablet prescribed for certain types of cancer in adults and some children. The cost of the drug, with and without insurance, can depend on several ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback